|Piramal Life Sciences Limited, is an independent research driven drug Company that was recently demerged from Piramal Healthcare Limited (Formerly know as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.
PLSL is focused on four therapeutic areas. Cancer, Diabetes, Inflammation and Infectious Diseases. The Company has a pipeline of fourteen compounds, including four in clinical trials. PLSL's lead chemical compound, a Cdk-4 inhibitor, has completed two phase 1 studies and is being tested in another Phase I/II trials for Multiple Myeloma. PLSL has drug discovery and developments agreements with Eli Lilly & Company and Merck & Company, two of the leading pharmaceuticals companies in the world.
PLSL is expected to be listed on the National Stock Exchange and the Bombay Stock Exchange by June 2008.
-Piramal Life Sciences gets its shares listed in the Stock Exchange.
-Piramal receives approval for clinical trial of two drugs
-Piramal Life Sciences Limited has received regulatory approval for the initiation of a Phase I study of a new cancer compound, P-1446A-05, in Canada
-Piramal Life Sciences initiates Phase II trials of P276 for Mantle Cell Lymphoma
-Piramal Life Sciences receives DCGI Approval to conduct two Phase I/II Combination studies of it's cancer molecule P276 for pancreatic, and head and neck cancer.
-Piramal Life Sciences changes its Share Transfer Agent from M/s. Freedom Registry Ltd. to M/s. Link Intime India Pvt. Ltd.
-Piramal Life Sciences initiates Phase II Trials for P1736-05 for Type II Diabetes in India and Europe
-Mr. Ankit Sheth has been appointed as Company Secretary of the Company.
-The company name has been changed from Piramal Life Sciences Limited to Piramal Phytocare Limited .
-The trading symbol of the Company be changed from PIRLIFE to PIRPHYTO.